PRIMROSE

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

Retrieved on: 
Wednesday, May 25, 2022

GENEVA, Switzerland May 25, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.

Key Points: 
  • GENEVA, Switzerland May 25, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.
  • The encouraging data presented at these important medical congresses highlight the differentiated therapeutic potential of linzagolix to better address the individual needs of women with uterine fibroids and endometriosis, said Dr. Brandi Howard, Chief Clinical Officer of ObsEva.
  • These data demonstrate that linzagolix with or without add-back therapy (ABT) significantly reduced heavy menstrual bleeding due to uterine fibroids.
  • Linzagolix is an investigational novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile1,2,3.

Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

Retrieved on: 
Monday, November 22, 2021

If approved, we believe linzagolix will address a significant unmet need in offering a more individualized treatment option for a broader range of women.

Key Points: 
  • If approved, we believe linzagolix will address a significant unmet need in offering a more individualized treatment option for a broader range of women.
  • With its unique dosing options, linzagolix has the potential to significantly advance medical options for women, stated Elizabeth Garner, MD, MPH, Chief Medical Officer of Obseva.
  • Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU.
  • Obseva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product.

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo

Retrieved on: 
Wednesday, October 20, 2021

Key takeaway: Once daily treatment of 200 mg linzagolix without ABT reduced uterine volume by 39% after 24 weeks.

Key Points: 
  • Key takeaway: Once daily treatment of 200 mg linzagolix without ABT reduced uterine volume by 39% after 24 weeks.
  • This single-center, open-label, exploratory study was designed to assess the efficacy and safety of linzagolix in the treatment of symptomatic adenomyosis.
  • Linzagolix is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile1,2,3.
  • Linzagolix has completed clinical trial development for the treatment of heavy menstrual bleeding associated with uterine fibroids and is currently in late-stage clinical development for the treatment of pain associated with endometriosis.